These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3309956)

  • 1. Growth factors in the prostate.
    Wilson EM; Smith EP
    Prog Clin Biol Res; 1987; 239():205-33. PubMed ID: 3309956
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tumor-derived growth factors--transforming growth factor].
    Umeda M
    Nihon Rinsho; 1986 Jan; 44(1):163-8. PubMed ID: 3514991
    [No Abstract]   [Full Text] [Related]  

  • 3. Peptide growth factors: current status and therapeutic opportunities.
    Sporn MB; Roberts AB
    Important Adv Oncol; 1987; ():75-86. PubMed ID: 2456983
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate-derived growth factors.
    Parrish RF; Heston WD; Pletscher LS; Tackett R; Fair WR
    Prog Clin Biol Res; 1984; 145():181-95. PubMed ID: 6201874
    [No Abstract]   [Full Text] [Related]  

  • 5. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
    Tang B; de Castro K; Barnes HE; Parks WT; Stewart L; Böttinger EP; Danielpour D; Wakefield LM
    Cancer Res; 1999 Oct; 59(19):4834-42. PubMed ID: 10519393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of prostatic growth and function by peptide growth factors.
    Culig Z; Hobisch A; Cronauer MV; Radmayr C; Hittmair A; Zhang J; Thurnher M; Bartsch G; Klocker H
    Prostate; 1996 Jun; 28(6):392-405. PubMed ID: 8650077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Origin and reversibility of malignancy.
    Sachs L
    Carcinog Compr Surv; 1985; 10():23-33. PubMed ID: 3904990
    [No Abstract]   [Full Text] [Related]  

  • 8. Growth factors as mediators of androgen action during male urogenital development.
    Cunha GR
    Prostate Suppl; 1996; 6():22-5. PubMed ID: 8630224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
    Algarté-Génin M; Cussenot O; Costa P
    Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth factors and transformation.
    Roberts AB; Sporn MB
    Cancer Surv; 1986; 5(2):405-12. PubMed ID: 3779661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stromal-epithelial interactions in normal and abnormal prostatic development.
    Cunha GR; Donjacour A
    Prog Clin Biol Res; 1987; 239():251-72. PubMed ID: 3309957
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hormonal and molecular biological factors in pathogenesis of prostate cancer].
    Zezerov EG
    Vopr Onkol; 2001; 47(2):174-81. PubMed ID: 11383453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Keratinocyte growth factor expression in hormone insensitive prostate cancer.
    Leung HY; Mehta P; Gray LB; Collins AT; Robson CN; Neal DE
    Oncogene; 1997 Aug; 15(9):1115-20. PubMed ID: 9285567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A growth factor in extracts of human prostatic tissue.
    Lawson RK; Story MT; Jacobs SC
    Prog Clin Biol Res; 1981; 75A():325-36. PubMed ID: 6175979
    [No Abstract]   [Full Text] [Related]  

  • 15. [Polypeptide growth factors in animal embryogenesis].
    Stoĭka RS; Kusen' SI
    Ontogenez; 1988; 19(3):229-39. PubMed ID: 3050668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of castration on the development of prostate adenocarcinoma from its precursor HGPIN and on the occurrence of androgen-independent, poorly differentiated carcinoma in TRAMP mice.
    Bono AV; Montironi R; Pannellini T; Sasso F; Mirone V; Musiani P; Iezzi M
    Prostate Cancer Prostatic Dis; 2008; 11(4):377-83. PubMed ID: 18379588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II.
    Song K; Cornelius SC; Danielpour D
    Cancer Res; 2003 Aug; 63(15):4358-67. PubMed ID: 12907605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine control of prostate cancer.
    Wilding G
    Cancer Surv; 1995; 23():43-62. PubMed ID: 7621473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of growth responsiveness to epidermal growth factor and enhanced production of alpha-transforming growth factors in ras-transformed mouse mammary epithelial cells.
    Salomon DS; Perroteau I; Kidwell WR; Tam J; Derynck R
    J Cell Physiol; 1987 Mar; 130(3):397-409. PubMed ID: 3494020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
    Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.